Alzheimer's: Are we on the right path to new drugs?
Written by Honor Whiteman
Published: Wednesday 30 November 2016
email
5
101Share
2
With the number of people living with Alzheimer's disease expected to almost triple by 2050, the race is on to find a treatment that can prevent or slow the condition. But last week saw another crack emerge in the already rocky path toward an effective Alzheimer's medication; pharmaceutical giant Eli Lilly announced the failure of what had previously been hailed a "breakthrough" in the treatment of the most common form of dementia.
[Alzheimer's disease description and drug]
Last week, Eli Lilly announced that the drug solanezumab had failed to slow cognitive decline in patients with mild Alzheimer's.
In a statement released last Wednesday, Eli Lilly revealed that their drug solanezumab failed to slow cognitive decline in a phase III clinical trial of more than 2,000 patients with mild Alzheimer's disease.
Solanezumab is a monoclonal antibody that aims to slow Alzheimer's progression by targeting and breaking down beta-amyloid plaques in the brain, which are clumps of protein thought to play a significant role in the disease.
http://www.medicalnewstoday.com/articles/314442.php
